Clinical significance of E-cadherin, β-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma

Journal of Clinical Pathology

Volumn 66, Issue 11, 2013, Pages 937-945

  Zhang, Hua ^a   Liu, Jun ^a   Yue, Dongsheng ^a   Gao, Liuwei ^a   Wang, Daowei ^a   Zhang, Hongdian ^a   Wang, Changli ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CALVASCULIN; TUMOR MARKER; UVOMORULIN; VIMENTIN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; SURVIVAL RATE; TISSUE DIFFERENTIATION;

IMMUNOHISTOCHEMISTRY; LUNG CANCER; ONCOLOGY;

BETA CATENIN; CADHERINS; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; S100 PROTEINS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VIMENTIN;

EID: 84888306817     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-201467     Document Type: Article

References (47)

1. Wen C, Dehnel T. China wrestles with lung cancer. Lancet Oncol 2011;12:15.
2. Jemal A, Siegel R, Ward E. Cancer statistics 2008. CA Cancer J Clin 2008;58:71-96.
3. Sugimura H, Nichols FC, Yang P, et al. Survival after recurrent non-small-cell lung cancer after complete pulmonary resection. Ann Thorac Surg 2007;83:409-18.
4. Rossi A, Ricciardi S, Maione P, et al. Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer 2009;66:141-9.
5. Rosell R, Perez-Roca L, Sanchez JJ, et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One 2009;4:e5133.
6. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non-squamous non-small cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34.
7. Kupferman ME, Jiffar T, El-Naggar A, et al. TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene 2010;29:2047-59.
8. Burdsal CA, Damsky CH, Pedersen RA. The role of E-cadherin and integrins in mesoderm differentiation and migration at the mammalian primitive streak. Development 1993;118:829-44.
9. Iwatsuki M, Mimori K, Yokobori T, et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 2010;101:293-9.
10. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
11. Gibbons DL, Lin W, Creighton CJ, et al. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev 2009;23:2140-51.
12. Korpal M, Lee ES, Hu G, et al. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008;283:14910-14.
13. Lee YC, Wu CT, Chen CS, et al. E-cadherin expression in surgically-resected non-small cell lung cancers-a clinicopathological study. Thorac Cardiovasc Surg 2000;48:294-9.
14. Kase S, Sugio K, Yamazaki K, et al. Expression of E-cadherin and β-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res 2000;6:4789-96.
15. Choi YS, Shim YM, Kim SH, et al. Prognostic significance of E-cadherin and β-catenin in resected stage I non-small cell lung cancer. Eur J Cardiothorac Surg 2003;24:441-9.
16. Kimura K, Endo Y, Yonemyra, et al. Clinical significance of S100A4 and E-cadherin-related adhesion molecules in non-small cell lung cancer. Int J Oncol 2000;16:1125-31.
17. Chiu CG, Chan SK, Fang ZA, et al. Beta-catenin expression is prognostic of improved non-small cell lung cancer survival. Am J Surg 2012;203:654-9.
18. Al-Saad S, Al-Shibli K, Donnem T, et al. The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small cell lung cancer. Br J Cancer 2008;99:1476-83.
19. Richardon F, Young GD, Sennello R, et al. The evaluation of E-cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- and third-line therapy. Anticancer Res 2012;32:537-52.
20. Soltermann A, Tischler V, Arbogast S, et al. Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res 2008;14:7430-7.
21. Matsubara D, Niki T, Ishikawa S, et al. Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes. Cancer Sci 2005;96:844-57.
22. Tsuna M, Kageyama S, Fukuoka J, et al. Significance of S100A4 as a prognostic marker of lung squamous cell carcinoma. Anticancer Res 2009;29:2547-54.
23. Yu J, Shi R, Zhang D, et al. Expression of integrin-linked kinase in lung squamous cell carcinoma and adenocarcinoma: correlation with E-cadherin expression, tumor microvessel density and clinical outcome. Virchows Arch 2011;458:99-107.
24. Prudkin L, Liu DD, Ozburn NC, et al. Epithelial-to-Mesenchymal Transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol 2009;22:668-78.
25. Pirinen RT, Hirvikoski P, Johansson RT, et al. Reduced expression of alpha-catenin, beta-catenin, and gamma-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer. J Clin Pathol 2001;54:391-5.
26. Dauphin M, Barbe C, Lemaire S, et al. Vimentin expression predicts the occurrence of metastases in non-small cell lung carcinomas. Lung Cancer 2013;pii:S0169-5002(13)00116-5.
27. Chikaishi Y, Uramoto H, Tanaka F, et al. The EMT status in the primary tumor does not predict postoperative recurrence or disease-free survival in lung adenocarcinomas. Anticancer Res 2011;31:4451-6.
28. Hommura F, Furuuchi K, Yamazaki K, et al. Increased expression of β-catenin predicts better prognosis in non-small cell lung carcinomas. Cancer 2002;94:752-8.
29. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th edn. New York, NY: Springer-Verlag, 2002.
30. Liu LK, Jiang XY, Zhou XX, et al. Up-regulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome. Mod Pathol 2010;23:213-24.
31. Hirata T, Fukuse T, Naiki H, et al. Expression of E-cadherin and lymph node metastasis in resected non-small cell lung cancer. Clin Lung Cancer 2001;3:134-40.
32. Zhang Y, Han Y, Zheng R, et al. Expression of Frat1 correlates with expression of β-catenin and is associated with a poor clinical outcome in human SCC and AC. Tumour Biol 2012;33:1437-44.
33. Liu D, Huang C, Kameyama K, et al. E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer. Ann Thorac Surg 2001;71:949-54.
34. Tamura M, Ohta Y, Tsunezuka Y, et al. Prognostic significance of dysadherin expression in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 2005;130:740-5.
35. Nakashima T, Huang C, Liu D, et al. Neural-cadherin expression associated with angiogenesis in non-small-cell lung cancer patients. Br J Cancer 2003;88:1727-33.
36. Nozawa N, Hashimoto S, Nakashima Y, et al. Immunohistochemical alpha- and beta-catenin and E-cadherin expression and their clinic-pathological significance in human lung adenocarcinoma. Pathol Res Pract 2006;202:639-50.
37. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009;119:1429-37.
38. Richardson F, Young GD, Sennello R, et al. The evaluation of E-cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy. Anticancer Res 2012;32:537-52.
39. Shintani Y, Okimura A, Sato K, et al. Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann Thorac Surg 2011;92:1794-804.
40. Suda K, Tomizawa K, Fujii M, et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 2011;6:1152-61.
41. Stein U, Arlt F, Walther W, et al. The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology 2006;131:1486-500.
42. Boye K, Maelandsmo GM. S100A4 and metastasis: a small actor playing many roles. Am J Pathol 2010;176:528-35.
43. Takenaga K, Nakamura Y, Sakiyama S. Expression of antisense RNA to S100A4 gene encoding an S100-related calcium-binding protein suppresses metastatic potential of high-metastatic Lewis lung carcinoma cells. Oncogene 1997;14:331-7.
44. De Petris L, Orre LM, Kanter L, et al. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer. Lung Cancer 2009;63:410-17.
45. Jung EA, Cho HD, Lee J-H, et al. Clinicopathological Significance of S100A4 Expression in Non-small Cell Lung Carcinomas. The Korean Journal of Pathology 2010;44:477-82.
46. Kwak JM, Lee HJ, Kim SH, et al. Expression of protein S100A4 is a predictor of recurrence in colorectal cancer. World J Gastroenterol 2010;16:3897-904.
47. Keirsebilck A, Bonne S, Bruyneel E, et al. E-cadherin and metastasin (mts-1/S100A4) expression levels are inversely regulated in two tumor cell families. Cancer Res 1998;58:4587-91.